Resectable Pancreatic Cancer Clinical Trial
Official title:
Nimotuzumab Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Resectable Pancreatic Cancer: a Propensity Score Matching Analysis
This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).
This trial is a retrospective, observational study based on real-world data obtained from the Health Information System (HIS) of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05209074 -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
| Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
| Recruiting |
NCT02243007 -
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05679050 -
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Withdrawn |
NCT01694589 -
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
|
Phase 0 | |
| Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01298011 -
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04810910 -
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
|
Phase 1 | |
| Completed |
NCT01992705 -
Borderline Pancreas Study: FOLFIRINOX +SBRT
|
Early Phase 1 | |
| Recruiting |
NCT05624918 -
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT02047513 -
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02115022 -
EUS vs. MDCT in Pancreatic Malignancy
|
||
| Recruiting |
NCT03492671 -
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT05546411 -
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06172036 -
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
|
Phase 2 | |
| Recruiting |
NCT05788744 -
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04737551 -
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
|
||
| Recruiting |
NCT03822936 -
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03435536 -
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
|
N/A |